The ECE1 Knockout HAP1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population carrying a targeted disruption of the human ECE1 gene in the HAP1 cell background. Generated by transient expression of Cas9 nuclease and an ECE1-specific guide RNA, this non-clonal cell pool enables loss-of-function studies without the need for single-cell isolation. By eliminating ECE1 gene function across the population, researchers can investigate the biological roles of endothelin-converting enzyme-1 in a genetically amenable host system. This polyclonal format is well-suited for screening experiments, functional validation, and downstream applications where a mixed knockout population offers technical and statistical advantages over clonal derivatives.
The HAP1 cell line is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia (CML) line. Its near-haploid karyotype??retaining a single copy of most chromosomes??makes it an exceptionally clean genetic background for CRISPR-based knockout studies, as disruption of a single allele typically yields a functional null phenotype. The CML origin also provides a cell model that retains features of hematologic malignancy, including constitutive kinase activity relevant to growth factor?Cindependent proliferation. Combined with robust growth properties and established protocols for genetic perturbation, HAP1 cells have become a standard platform for arrayed and pooled knockout screens, gene?Cdrug interaction studies, and mechanistic pathway dissections.
Endothelin-converting enzyme-1 (ECE1) is a membrane-bound zinc metalloprotease responsible for the final proteolytic activation of big endothelin-1 to the potent vasoactive peptide endothelin-1. This processing step is essential for the production of mature endothelin-1, which then engages its cognate G protein?Ccoupled receptors, ETA (EDNRA) and ETB (EDNRB). Upon ligand binding, these receptors couple primarily to Gq proteins, activating phospholipase C beta (PLCB) to generate inositol trisphosphate (IP3) and diacylglycerol, triggering calcium release from intracellular stores and activation of protein kinase C (PKC). Downstream, this cascade converges on the mitogen-activated protein kinase (MAPK) pathway, including ERK1/2, to promote vasoconstriction, cell proliferation, and migration. ECE1 expression and activity are regulated by diverse upstream stimuli such as TGF???1, TNF???, shear stress, and hypoxia, and the enzyme also processes other substrates including bradykinin and substance P, positioning it at a key intersection of vascular homeostasis and neuropeptide signaling.
Disruption of ECE1 in the HAP1 near-haploid background generates a powerful model system for dissecting endothelin-dependent biology. Because HAP1 cells contain a single functional copy of the ECE1 locus, CRISPR-mediated editing eliminates the enzyme??s activity, effectively phenocopying a homozygous null state without the need for biallelic targeting strategies. This loss-of-function model is particularly valuable for studying endothelin-1?Cmediated autocrine and paracrine signaling in the absence of confounding vasoactive feedback mechanisms found in intact vasculature. The hematopoietic origin of HAP1 also allows exploration of endothelin??s emerging roles in inflammation, leukocyte adhesion, and cancer cell interactions??areas increasingly recognized as relevant to cardiovascular and oncologic pathology.
Research applications for the ECE1 Knockout HAP1 Polyclonal Cells span endothelin processing studies, ECE inhibitor validation, and functional genomics screening. Typical experimental readouts include western blotting for ECE1 protein, RT?qPCR measurement of ECE1 mRNA, and endothelin-1 ELISA to quantify secreted peptide levels. For signaling analyses, calcium flux assays capture receptor-proximal readouts, while cell proliferation and migration assays assess mitogenic and motile phenotypes. These cells also find use in neuropeptide processing research, drug target deconvolution, and mechanistic studies of vascular smooth muscle contraction pathways. For detailed product specifications or technical support, contact Ascent Research.
